Eagle Bay Advisors’s Editas Medicine EDIT Stock Holding History

Eagle Bay Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-873	Closed	-$23K	–	484
2021 Q4	$23K	Buy	+873	New	+$30K	0.01%	535

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Eagle Bay Advisors's EDIT Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 873 shares — an estimated $23K sold.

Eagle Bay Advisors first reported a position in EDIT in Q4 2021 and held it in 1 quarter. The position peaked at $23K in Q4 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

Eagle Bay Advisors reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 873 Editas Medicine shares in Q1 2022, an estimated $23K.
Eagle Bay Advisors first reported a position in Editas Medicine in Q4 2021 and held it in 1 quarter.
Eagle Bay Advisors's Editas Medicine position peaked at $23K in Q4 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.